This recombinant monoclonal antibody is developed as a research-grade biosimilar to ABBV-368, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor expressed primarily on activated T cells that plays a critical role in T cell proliferation, survival, and effector function. Upon binding to its ligand OX40L, this receptor delivers signals that enhance T cell-mediated immune responses and promote immunological memory. TNFRSF4 has emerged as an important therapeutic target in immuno-oncology, as its activation can enhance anti-tumor immunity by promoting T cell expansion and overcoming immunosuppressive mechanisms within the tumor microenvironment.
ABBV-368 represents an agonistic antibody designed to stimulate TNFRSF4 signaling and enhance anti-tumor immune responses, particularly in combination with other immunotherapies. This biosimilar antibody provides researchers with a valuable tool for investigating TNFRSF4-mediated immune modulation, studying T cell biology, and exploring combination immunotherapy strategies in preclinical cancer models. It supports mechanistic studies of costimulatory pathways and therapeutic development in oncology research.
Email: support@cusabio.com
Distributors Worldwide